Gloxitel-Beta Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 50 mg, formulated for extended-release administration. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. The extended-release formulation ensures a sustained therapeutic effect, enhancing patient compliance by allowing once-daily dosing. Gloxitel-Beta is indicated for the management of hypertension, particularly in patients requiring combination therapy for optimal blood pressure control. It may also be beneficial in patients with concomitant cardiovascular conditions such as ischemic heart disease or heart failure, where beta-blockade is advantageous. The combination addresses multiple pathophysiological mechanisms involved in hypertension, providing additive antihypertensive effects. Caution is advised in patients with bradycardia, severe hepatic or renal impairment, and in those with a history of hypersensitivity to either component. Regular monitoring of blood pressure, renal function, and heart rate is recommended during therapy. Gloxitel-Beta Tablet ER should be used under medical supervision to optimize therapeutic outcomes and minimize adverse effects.